Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …

regenerative medicine

Guest Blog: “How to deliver the magic bullet in regenerative medicine”

One concept that worked well at for World Stem Cells & Regenerative Medicine Congress 2015 was the round table sessions. To be honest, I arrived a sceptic wondering how much more I would gain from the sessions, perhaps an hour sitting uncomfortably trying to engage in debate. The answer – a window into each company’s current work or the question …

The impact of 3D printed organs on the future of regenerative medicine

I recently read an interesting article in The Economist on regulations surrounding lung transplants; in particular on the issue of children receiving adult lungs. The FDA normally requires children to only receive organs from other children, but these are not as readily available as adult organs. In recent years, besides the development of artificial lungs, there has been a lot …